"😎Glad to see our data, hitting the press! 🚀
✔️ Driven by these findings, we’ve just kicked off an RCT 🎲 in the department comparing VKA💊 versus DOACs in NS. 💥Likely to move the needle on anticoagulation strategies in NS . https://t.co/W5TGhaQoKq
@SaynaNorouzi@AKronbichler@myadla@SwarnalathaGud2
*When Positivity Misleads: Recognizing False Signals in SAB Testing*
***********************
⚡SAB positivity can represent artefact rather than true immunologic risk
⚡High MFI alone is unreliable without pattern and clinical context
⚡A broad, tapering (“long-tail”) pattern suggests non-specific reactivity
⚡Lack of sensitization history should prompt cautious interpretation
⚡FlowPRA and FCXM discordance helps identify non-clinical antibodies
⚡Absence of a shared epitope supports non-specific binding
⚡Misinterpretation can lead to false DSA assignment and inflated cPRA
⚡Result in unnecessary exclusion of compatible donors
⚡Always interpret SAB results in integration with clinical and laboratory correlation
⚡Pattern recognition is more reliable than numerical thresholds
#KKNephBytes #Immunology
@arvindcanchi@DrAkshayaJ@drshyambansal@hardik4u24@isn_india@priti899@suhalikapath@AnjanaGopal9@raja_1980@dr_sourabha@iamnephrologist
Hi!
We are currently analyzing HLA-DQ antibodies, and our observations suggest a predominant role of the beta chain in driving immunogenicity. However, the alpha chain significantly modulates this response, and in some cases, we are seeing isolated alpha-chain–targeted epitopes contributing to DSA formation.
These findings highlight the complexity of DQ heterodimer immunogenicity—both chains cannot be interpreted in isolation. Further population-based and eplet-level analyses are needed to better understand these patterns and their clinical relevance.
*HLA-DQ Antibodies: The Silent Cracker That Starts the Blast*
***************************
⚡HLA-DQ antibodies are the most common de novo DSA
⚡HLA-DQ DSA have the worst graft outcomes (ABMR, TG, graft loss)
⚡DQ mismatch carries the highest risk of sensitization (↑cPRA)
⚡ HLA-DQ has dual polymorphism (α + β chains)
⚡Can form multiple heterodimers (cis + trans pairing)
⚡ More heterodimers → more epitopes → higher immunogenicity
⚡ HLA-DQ shows low expression but high pathogenicity
⚡ Expression is delayed but sustained → chronic rejection
⚡ DQ antibodies activate Akt / S6 / IL-6 pathways
⚡ Current matching underestimates DQ risk
⚡ Eplet/pairing-based analysis > antigen matching
#KKNephBytes #Immunology
@arvindcanchi@DrAkshayaJ@drshyambansal@hardik4u24@isn_india@priti899@suhalikapath@JJayameena